TABLE 8.
Pathways significantly altered by 1α,25(OH)2D3 treatment of primary human skeletal muscle cells using DAVID analysis and associated databases
| Pathway term (gene count) | p | Database |
|---|---|---|
| Focal adhesion (61) | 7.52E−12 | KEGG |
| ECM-receptor interaction (35) | 3.64E−11 | KEGG |
| Integrin signaling (68) | 3.15E−10 | Panther |
| Integrin signaling (24) | 2.72E−05 | Reactome |
| Gap junction (23) | 7.79E−04 | KEGG |
| Axon guidance (30) | 6.74E−04 | KEGG |
| Signaling by PDGF (20) | 7.06E−05 | Reactome |
| JAK/STAT signaling (10) | 0.003 | Panther |
| Pathways in cancer (57) | 0.005 | KEGG |
| Signaling by NGF (33) | 0.006 | Reactome |
| Regulation of actin cytoskeleton (40) | 0.006 | KEGG |
| Metabolism of nucleotides (17) | 0.014 | Reactome |
| p53 pathway (16) | 0.014 | Panther |
| Interferon-signaling (11) | 0.017 | Panther |
| Muscle contraction (9) | 0.022 | Reactome |
| Terpenoid backbone biosynthesis (6) | 0.028 | KEGG |
| Cell adhesion molecules (24) | 0.048 | KEGG |